



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/922,694	08/07/2001	Atsushi Suzuki	210377US0	8724

22850 7590 04/12/2005

OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C.
1940 DUKE STREET
ALEXANDRIA, VA 22314

EXAMINER

HAWES, PILI ASABI

ART UNIT PAPER NUMBER

1615

DATE MAILED: 04/12/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

09/922,694

Applicant(s)

SUZUKI ET AL.

Examiner

Pili A. Hawes

Art Unit

1615

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 19 April 2004.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 2-6, 10-16 and 30-39 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 2-6, 10-16 and 30-39 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☒ All b) ☐ Some * c) ☐ None of:
- 1) ☒ Certified copies of the priority documents have been received.
 - 2) ☐ Certified copies of the priority documents have been received in Application No. _____.
 - 3) ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☒ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date 6-28-2004.
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: _____

DETAILED ACTION

Action Summary

Acknowledgement is made of the receipt of applicant's amendment and request for reconsideration, filed April 19, 2004.

Claims 8 and 20-29 have been cancelled. Claims 2-6, 10-16 and 30-39 are active in this action.

In view of further review of claim 10, the scope has been reevaluated and prosecution is being continued.

Claims 2-6, 10-16, and 30-39 are rejected.

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 2-6, 10-16, 30-39 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-11 of U.S.

Patent No. 6,310,100 B1. Although the conflicting claims are not identical, they are not

Art Unit: 1615

patentably distinct from each other because both inventions disclose treatments for hypertension comprised of ferulic acid or a derivative thereof. The therapeutic compositions comprising ferulic acid and its derivatives may further comprise pharmaceutical products, nutritional supplements or products, and foods. The reference does not specifically claim chlorogenic or caffeic acid in combination with ferulic acid, but in claim 5 it does disclose a composition "consisting essentially of ferulic acid or a derivative thereof, and at least one other anti-hypertensive compound," which would encompass chlorogenic and caffeic acid. One of ordinary skill in the art would be motivated to combine chlorogenic and caffeic acids, which are known anti-hypertensive agents to a composition comprising ferulic acid with the expectation of successful treatment of hypertension with such a composition.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein

Art Unit: 1615

were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 2-6, 10-16, and 30-39 are rejected under 35 U.S.C 103(a) as being unpatentable over Abraham (XP-001148404, 1996) in view of Hsu (US 5,958,417) and further in view of Ghai et al. (US 5,955,269). The claims are to a composition comprised of ferulic acid and caffeic acid, chlorogenic acid or a combination of caffeic acid and chlorogenic acid. Abraham discloses a dietary constituent comprising a combination of chlorogenic acid, caffeic acid and ferulic acid (Table 1). These phenolic compounds occur in some of the commonly consumed vegetables, fruits and beverages (page 19, column 1). Abraham does not expressly disclose that the referenced dietary constituents are used in the treatment of hypertension. However, Hsu ('417) addresses this limitation by disclosing that the active principles, chlorogenic acid and caffeic acid, found in the herbal substance, Crataegus, are used to treat hypertension (column 2, lines 59-61).

One of ordinary skill in the art would have been motivated to combine the dietary constituents disclosed by Abraham to make a composition for treatment of hypertension as discussed by Hsu because of the need for alternatives to conventional pharmaceuticals currently used to treat hypertension, with an expectation of fewer harmful side effects.

The examiner cites Ghai et al. (US 5, 955,269) that discloses processed foods, or foods fortified with nutraceuticals and the methods of adjusting the combination and level of these nutraceutical compounds in a supplement or in food products to achieve added nutritional or therapeutic benefit (col. 25, lines 1-3, col. 26, lines 43-50 and col. 27, lines 19-25). The reference further teaches that nutraceutical compounds can be administered by inhalation; orally as tablets, capsules, or liquid preparations; controlled release formulations; or as food supplements (col. 25-26). Table 1 (col. 23, lines 41-65) further discloses examples of phenolic acids, such as caffeic, chlorogenic, and ferulic acids as examples of food substances that can be used as nutraceuticals. The reference does not disclose the anti-hypertensive properties of caffeic, chlorogenic, or ferulic acids. However, the teachings of Hsu, as discussed above, do address this limitation. It would have been obvious to one of ordinary skill in the art to combine ferulic acid with chlorogenic acid and caffeic acid as taught by Ghai to obtain synergistic effects in the treatment of hypertension. Further, it would have been obvious to one of ordinary skill in the art at the time the invention was made to use a nutraceutical supplement to fortify foods or beverages as taught by Ghai, and to use said foods or beverages in the treatment of hypertension as taught by Hsu, with an expectation of reduced toxicity.

Conclusion

Claims 2-6, 10-16, and 30-39 are rejected.


Art Unit: 1615

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Pili A. Hawes whose telephone number is 571-272-8512. The examiner can normally be reached on 8-4:30 M-F.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thurman Page can be reached on 571-272-0602. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

P. A. Hawes
Examiner-1615


THURMAN K. PAGE
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600